One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers
18. juni 2018 oppdatert av: Johnson & Johnson Vision Care, Inc.
One Month Daily Wear Clinical Evaluation of Three Prototype Soft Contact Lenses in a Population of Habitual and Neophyte Contact Lens Wearers
There will be four study lenses tested; one marketed lens, and three prototype study lenses.
Subjects will be randomized to one of the four study lenses which will be worn in a daily wear modality, with a two week replacement.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
80
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600 006
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 39 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- The subject must be between 18 and 39 years of age.
- The subject must be able to read and understand English.
- The subject read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
- The subject must not have been a participant in a contact lens or contact lens solution study/investigation in the previous seven days.
- The subject must be willing to wearthe study lenses for at least 6 hours per day, 7 days per week (e.g. does not regularly swim).
- The subject must appear able and willing and able to the adhere to the instructions set forth in this clinical protocol.
- The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -4.00D in each eye.
- The subject's refractive astigamatism must be less than or equal to -1.00D in both eyes.
- The subjet must have best corrected visual acuity of 20/30 (6/9 or +0.20 logMAR) or better in each eye.
- The subject must require a visual correction in both eyes (no monofit or monovision allowed).
The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No amblyopia
- No evidence of lid abnormality or infection (including blepharitis/meibomitis)
- No conjunctival abnormality or infection.
- No clinically significant slit lamp findings (i.e. stromal edema, vascularization, corneal scaring, infiltrates or abnormal opacities).
- No other active ocular diseases.
Exclusion Criteria:
- Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Any systemic diseases, autoimmune disease, or use of medication, which may interfere with contact lens wear.
- Clinically significant (Grade 3 or 4) corneal edeam, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid permeable contact lens wear.
- Pregnancy or lactation (subjects who become pregnant during the study will be discontinued).
- No extended wear in the last 3 months.
- Diabetes.
- Infectious diseases (e.g. hepatitis, tuberculosis) or immunosuppressive disease (e.g. HIV).
- Has had refractive surgery.
- Employee of VRF with direct involvement in the study or a family member of the clinic.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: etafilcon A
Marketed control soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
|
|
Eksperimentell: Prototype E1
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andre navn:
|
|
Eksperimentell: Prototype E2
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andre navn:
|
|
Eksperimentell: Prototype E3
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Corneal Staining (Area)
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Staining Area was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 11-point scale (i.e.
Grade 0= 0% of region covered, Grade 1 =10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4= 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered,Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered and Grade 10 = 100% of region covered).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Depth)
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Staining Depth was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 4-point scale (i.e.
Grade 0= None, Grade 1 =Superficial epithelial, Grade 2 = Full epithelial, Grade 3 =stromal glow).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Type)
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Staining was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 5-point scale (i.e.
Grade 0= None, Grade 1 =Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate and Grade 4 = Patch (greater or equal to 1mm).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Limbal Conjunctival Redness
Tidsramme: Baseline and 2-Week Follow-up
|
Limbal Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Limbal Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for limbal redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Bulbar Conjunctival Redness
Tidsramme: Baseline and 2-Week Follow-up
|
Bulbar Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Bulbar Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for bulbar redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Visual Acuity (LogMAR)
Tidsramme: 4-Week Follow-up
|
Visual Acuity (LogMAR) was assessed bionocularly at the 4-week follow-up evaluations.
The average visual acuity (LogMAR) for each lens was reported.
|
4-Week Follow-up
|
|
Lens Fitting Characteristics
Tidsramme: Post Lens Fitting and 4-Week Follow-up
|
Lens fit was assessed for each subject eye at post lens fitting and 4- week follow-up evaluations.
Lens fit is a binary response as acceptable or unacceptable lens fit.
The percentage of eyes with acceptable lens fit was reported.
|
Post Lens Fitting and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Burning/Stinging)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Burning/Stinging was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Corneal Edema
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Edema was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Conjunctival Injection
Tidsramme: Baseline and 4-Week Follow-up
|
Conjunctival Injection was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Neovascularization
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Neovascularization was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining
Tidsramme: Baseline and 4-Week Follow-up
|
Corneal Staining was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Tarsal Abnormalities
Tidsramme: 1-, 2- and 4-Week Follow-up
|
Tarsal abnormalities were assessed using a biomicroscope at baseline, post lens fitting, 1-, 2- and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0, 1, 2, 3 and 4) with grade 0 represents the absence of abnormalities and 1 to 4 representing successively worse abnormalities (i.e.
Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The percentage of eyes with Grade 3 or higher was reported.
|
1-, 2- and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Cloudy/Blurry/Hazy)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Cloudy/Blurry/Hazy was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Dryness)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Dryness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Grittiness/Foreign Body Sensation)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Grittiness/Foreign Body Sensation was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Irritation/Discomfort)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Irritation/Discomfort was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Itchiness/Scratchiness)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Itchiness/Scratchiness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Lens Awareness)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Lens awareness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Redness)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Redness wasassessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Variable Vision)
Tidsramme: Baseline and 4-Week Follow-up
|
The Ocular symptom Variable Vision was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. februar 2014
Primær fullføring (Faktiske)
25. juni 2014
Studiet fullført (Faktiske)
25. juni 2014
Datoer for studieregistrering
Først innsendt
5. mars 2014
Først innsendt som oppfylte QC-kriteriene
6. mars 2014
Først lagt ut (Anslag)
7. mars 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. juni 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. juni 2018
Sist bekreftet
1. juli 2017
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CR-5146
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Ja
produkt produsert i og eksportert fra USA
Ja
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .